Philogen announces new collaboration with Janssen to discover small molecule therapeuticsPress Release 2021-11-24
Philochem, InterX and Scripps Research announce a Research Collaboration in the Field of DNA-Encoded Chemistry and Tumor TargetingPhilochem, InterX and Scripps Research Collaboration
Philochem, a wholly owned subsidiary of Philogen S.p.A., InterX, Inc and Scripps Research announce a research collaboration to develop a best-in-class tumor targeting agent for metastatic prostate cancer.
Philogen will be attending the PEGS Boston Virtual Summit from May 11th to 13th, 2021.
Alessandra Villa, Head of Antibody Research will give a lecture with the title “Targeted Immunocytokines” on May 12th.
Samuele Cazzamalli, Head of Small Molecule Therapeutics will give a lecture with the title: “Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting” on May 13th.
06/05/2021PRESS RELEASE - Notice of Q1 Results
Philogen S.p.A. will announce its maiden First Quarter 2021 Results on Wednesday 12th May 2021
A virtual briefing will be hosted for sell-side analysts at 10:00am EST / 14:00pm BST / 15:00pm CEST on Thursday 13th May 2021
13/04/2021PRESS RELEASE - PNAS
Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS
Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against healthy organs
OncoFAP-based molecules are currently being developed for the imaging and therapy of cancer
Philogen announces publication of the construction and application of an innovative DNA- encoded chemical library in Nature ChemistryPRESS RELEASE - NATURE CHEMISTRY
Study shows the generation of a high-quality stereo- and regiodefined DNA-encoded chemical library.
Identified ligands against tumor-associated antigens can serve as vehicles for pharmacodelivery applications.
Philogen will be attending the digital World ADC Europe Conference from March 8 to 11, 2021.
Dr. Samuele Cazzamalli - Head of Small Molecule Therapeutics - will give a Plenary Lecture on: “Small Molecule-Drug Conjugates: Getting Small to Enhance Targeting”.
Philochem announces a publication entitled: “Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of Small Molecule-Drug Conjugates targeting Carbonic Anhydrase IX”
Link to Paper
Philochem is happy to announce the start of an Innosuissecollaboration with ETH Zurich for the development of Macrocyclic DualPharmacophore DNA-Encoded Chemical Libraries.
The partners will synthesize andvalidate macrocycle-based libraries comprising more than one billion compounds.
These libraries will have a great potential for the identification of ligandsagainst target proteins of biomedical interest with antibody-like properties